Procedures and surgery in multiple myeloma: sampling, cell collection, and skeletal stability

Myeloma care may involve a marrow biopsy, cell collection, a catheter, vertebral augmentation, or fracture fixation. These procedures have different purposes. Most active myeloma requires systemic treatment, and removing one bone lesion does not establish control throughout the body. Before consenting, clarify whether the procedure is obtaining a diagnosis, supporting treatment, preserving function, or initiating a cellular-therapy pathway.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

An aspirate usually provides cells, while a core biopsy provides tissue architecture. Material may also be used for flow cytometry and genetic studies. These tests characterize the plasma-cell disorder; they do not drain myeloma from the marrow. The sampling plan and need for repetition should reflect the question that has to be answered. NICE myeloma investigation recommendations
CAR-T can also begin with apheresis, but the collected immune cells are used to manufacture the treatment product rather than to create a blood-forming stem-cell reserve. Manufacturing, release testing, possible bridging therapy, and lymphodepletion precede infusion. Collection does not guarantee that a product will be available on the original date, and disease change can alter the plan.
Before any procedure, make sure the team knows about allergies, infection, bleeding, kidney problems, and all current medicines. Identify who performs the final medication check. When several specialties are involved, changes to anticoagulants or steroids should be communicated rather than made independently without a shared record.

Quick answer

Full guide

If traveling to China for a procedure, confirm its exact name, objective, and prerequisites. Assessment, bed availability, and individual recovery can change timing. Descriptions such as minimally invasive or a one-day infusion cannot determine how long someone needs to remain near the treating center.

Marrow sampling supplies evidence rather than removing the disease

An aspirate usually provides cells, while a core biopsy provides tissue architecture. Material may also be used for flow cytometry and genetic studies. These tests characterize the plasma-cell disorder; they do not drain myeloma from the marrow. The sampling plan and need for repetition should reflect the question that has to be answered. NICE myeloma investigation recommendations

Disclose anticoagulation, platelet problems, previous bleeding, and local infection before the procedure. Any medication interruption should be directed by the clinical team. Ask about anesthesia, pain control, activity afterward, dressings, and the response to persistent bleeding or unexpectedly severe pain.

Existing slides or tissue may be suitable for review, so ask whether they can be borrowed before assuming another biopsy is required. Inadequate specimens, missing studies, or a changed disease picture can still justify new sampling. The clinician should explain its added value rather than present every procedure as an unexplained routine requirement.

Stem-cell collection and transplantation are separate stages

Before autologous transplantation, blood-forming stem cells are generally mobilized into the peripheral blood, collected by apheresis, and stored. Mobilization strategies differ according to earlier treatment, blood counts, and the center's approach. The machine separates the intended cells and returns other blood components; it is not an operation removing a block of marrow. IMWG mobilization and collection consensus

Venous access is assessed beforehand. Some people can use peripheral veins, while others need a temporary central catheter. Access should fit the required flow and purpose; an existing infusion port should not automatically be assumed suitable for apheresis. Ask about the site, infection and thrombosis risks, maintenance, and removal.

The laboratory must confirm that the collection is adequate. Additional sessions or a revised mobilization strategy may be needed, so the original calendar cannot be guaranteed for everyone. If the yield is insufficient, the team should explain the available next steps and their implications. Feeling well after collection does not establish that the necessary cell target has been achieved.

Autologous transplantation supports recovery after high-dose treatment

The patient's stored cells help restore blood formation following high-dose therapy. Reinfusion may resemble a transfusion, but much of the burden comes from conditioning and subsequent low blood counts, mucosal or gastrointestinal symptoms, infection risk, and recovery. Admission and observation arrangements depend on the institution and the individual. EBMT Handbook chapter on multiple myeloma

Preparation can address heart, lung, liver, kidney, infection, and nutritional issues, along with fertility and practical support. Ask about testing during the process, possible blood products, and emergency care. Reinfusion is not the end of recovery, and discharge does not establish immediate restoration of normal immune function.

Trials such as DETERMINATION inform the value and burden of autologous transplantation within an initial strategy, without guaranteeing permanent freedom from relapse for an individual. Maintenance and long-term monitoring can still follow. The decision should concern this full pathway rather than only the single hospital admission. DETERMINATION randomized study

A second autologous or an allogeneic transplant needs its own rationale

Tandem transplantation or another autologous procedure at relapse depends on disease characteristics, duration of earlier benefit, stored cells, and available alternatives. Two procedures are not automatically better than one. The proposal should explain the relevant evidence and additional toxicity, recovery, and expense.

Allogeneic transplantation uses donor cells and introduces different risks, including graft-versus-host disease. Its role in myeloma is limited, and ASTCT guidance emphasizes careful selection and a research context. It should not be described as an equivalent autologous procedure with a different cell source. ASTCT myeloma transplantation and cellular-therapy recommendations

Earlier cellular-therapy recommendations cannot define every current CAR-T treatment line because indications have changed. Apply current information for the actual product and country. A professional consensus can explain principles while its older access statements may require updating against later regulatory decisions.

CAR-T collection has a different objective

CAR-T can also begin with apheresis, but the collected immune cells are used to manufacture the treatment product rather than to create a blood-forming stem-cell reserve. Manufacturing, release testing, possible bridging therapy, and lymphodepletion precede infusion. Collection does not guarantee that a product will be available on the original date, and disease change can alter the plan.

China's 2025 national guidance includes selected myeloma CAR-T products and their use conditions. The receiving doctor should confirm whether the patient's previous therapy qualifies, whether the center is appropriately equipped, and how manufacture and observation will be organized, including later updates. Requirements for another country's product cannot simply be copied. National Health Commission anticancer medicine guidance

Fever, altered speech or awareness, and substantial new weakness after infusion need prompt action under the center's instructions. Leaving the area, driving, and further travel should follow the actual product and team requirements. The fact that infusion occurs on one day does not make the following day a safe or guaranteed return-home date.

Vertebral augmentation targets selected compression fractures

Myeloma-related vertebral compression fractures can cause persistent pain and limited activity. After appropriate imaging and assessment, some patients may benefit from cement augmentation through vertebroplasty or balloon kyphoplasty. Suitability depends on the pain source, fracture characteristics, spinal structure, neural compression, infection, and other factors. Back pain alone is not enough to establish an indication. IMWG consensus on vertebral cement augmentation

Ask whether the expected improvement concerns pain, mobility, structural support, or a combination, and what the procedure cannot address. Risks can include cement leakage, neurological injury, and infection, with individual relevance depending on anatomy and technique. Relief of pain does not eliminate the need for systemic myeloma treatment or bone-directed management.

New leg weakness, progressive numbness, or bladder or bowel dysfunction requires urgent assessment rather than simply booking an ordinary augmentation clinic. Neural symptoms can require a different emergency pathway, potentially involving spinal surgery and radiation specialists.

Fixation and spinal surgery address stability and function

An orthopedic team may recommend fixation for an established or impending fracture of a weight-bearing long bone. Spinal instability or selected compression problems may also require surgery. Antimyeloma drugs can control the disease but cannot guarantee immediate mechanical safety of a damaged bone. Local stabilization and systemic treatment sometimes need to be coordinated. IMWG bone-disease treatment guidance

Ask about the short-term risk without surgery, the function expected after it, weight-bearing restrictions, rehabilitation, and the timing of further anticancer treatment. Low counts, infection, and anticoagulants can affect scheduling and require shared decisions between hematology and surgery.

Bracing, protected activity, analgesia, and radiation may be part of the same discussion. A procedure being less invasive does not automatically make it the preferred choice. Likewise, a desire to walk again quickly should be expressed clearly but translated into a safe plan based on structural assessment rather than unreviewed exercise.

Prepare for recovery as carefully as for consent

Before any procedure, make sure the team knows about allergies, infection, bleeding, kidney problems, and all current medicines. Identify who performs the final medication check. When several specialties are involved, changes to anticoagulants or steroids should be communicated rather than made independently without a shared record.

Before leaving the procedure area or hospital, understand dressing or catheter care, allowed activity, the next review, and the response to fever, bleeding, or neurological change. If a relative will provide care, they should have an opportunity to demonstrate understanding. A written page alone may be inadequate when language or unfamiliar equipment makes the instructions difficult to follow.

For care in China, divide renminbi estimates into assessment, procedure, anesthesia, devices or consumables, admission, medicines, and rehabilitation support. Clarify whether complications or delay create separate charges. Collection and transplantation, a cell product and its monitoring, or vertebral treatment and systemic care should not be collapsed into an undefined total.

The central question is what specific problem the procedure can solve, which alternatives are reasonable, and how myeloma care continues afterward. Understanding that purpose and the transition into recovery gives the patient a firmer basis for a decision than the technology's name alone.